鼻咽癌N<sub>0</sub>‐N<sub>1</sub>期患者Ⅱb区临床靶区剂量优化策略及可行性分析

doi:10.3760/cma.j.cn113030-20210901-00336

摘要
图/表
参考文献
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的明确鼻咽癌N₀‐N₁期患者Ⅱ_b区淋巴结预防照射剂量CTV_60Gy优化至CTV_50Gy的安全性以及对腮腺保护的剂量优势和临床价值,了解PET‐CT及弥散加权成像（DWI）对颈部可疑阳性淋巴结（最大横断面短径≥5 mm但<10 mm）的诊断价值。方法回顾性分析2015年6月至2017年3月收治的N₀‐N₁期初治非转移鼻咽癌157例,其中104例在多模态影像指导下进行上颈部Ⅱ_b区临床靶区优化,以Kaplan‐Meier法进行生存分析,单因素、多因素回归分析颈部淋巴结复发模式,配对t检验比较剂量优化前后靶区及腮腺剂量参数差异。结果 N₁期行对侧单颈Ⅱ_b区优化60例,行双颈Ⅱ_b区优化25例（仅咽后淋巴结转移者）;N₀期双颈Ⅱ_b区优化19例。共有3例患者出现颈部复发,均在高剂量区内。全组5年总生存率为93.3%,淋巴结无复发生存率、无局部复发生存率、无远处转移生存率和无瘤生存率分别为97.1%、91.3%、88.5%和80.8%。颈淋巴结复发与鼻咽局部复发有关,与咽后淋巴结状态无关。14例患者Ⅱ_b区内有可疑阳性颈淋巴结,最大横截面短径平均为7.1（5~9） mm,其中11例PET‐CT阳性,平均SUV_max为2.96（2.5~3.3）。优化后肿瘤体积的差异无统计学意义（P>0.05）,腮腺的D_mean、D_max、D_50%、V_26Gy显著低于常规计划（P<0.01）。结论鼻咽癌N₀‐N₁患者进行Ⅱ_b区CTV_60Gy至CTV_50Gy的剂量优化是安全的,腮腺及颈部周围正常组织受照剂量明显降低,对于未达诊断标准的小淋巴结需要结合PET‐CT及DWI等多模态成像进行个体化处理。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄文轩
	宗丹
	张彬
	王丽君
	张兰芳
	马承贤
	尹丽
	黄生富
	何侠

关键词 ：鼻咽肿瘤, 调强放射疗法, 临床靶区, 颈部淋巴结, 弥散加权成像

Abstract：Objective To determine the safety of prophylactic irradiation dose CTV_60Gyoptimized to CTV_50Gy for II_b region in patients with stage N₀‐N₁ nasopharyngeal carcinoma (NPC) and the dose advantage and clinical value for parotid gland protection, and to understand the diagnostic value of PET‐CT and diffusion‐weighted imaging (DWI) for suspicious positive lymph nodes in the neck (5 mm≤maximum short diameter<10 mm). Methods Clinical data of 157 patients with primary non‐metastatic NPC (N₀‐N₁) admitted to our hospital from June 2015 to March 2017 were retrospectively analyzed. 104 patients underwent II_b clinical target volume optimization guided by multimodal imaging system. Survival analysis was performed by Kaplan ‐ Meier method. Univariate/multivariate regression analysis was performed to analyze the pattern of cervical lymph node recurrence. Paired t‐test was used to compare the differences in target volume and parotid gland dose parameters before and after dose optimization. Results Sixty patients underwent single‐neck optimization in stage N₁, 25 patients received double‐neck optimization (only those with retropharyngeal lymph node metastasis), and 19 patients underwent double‐neck optimization in stage N₀. Three patients had cervical regional recurrence, all in‐field. The 5‐year overall survival rate was 93.3%. The lymph node recurrence‐free survival rate, local recurrence‐free survival rate, distant metastasis‐free survival rate and disease‐free survival rate were 97.1%, 91.3%, 88.5% and 80.8%, respectively. Cervical lymph node recurrence was associated with local recurrence in the nasopharynx, regardless of retropharyngeal lymph node status. Fourteen patients had suspicious positive cervical lymph nodes in II_b region, with a mean maximum short diameter of 7.1 (5~9) mm on the largest cross‐sectional plane, and 11 of them were positive on PET‐CT, with a mean SUV_max of 2.96 (2.5~3.3). There was no significant difference in GTV after optimization (P>0.05). D_mean, D_max, D_50% and V_26Gy of parotid gland were significantly lower than those of conventional plan (all P<0.01). Conclusions It is safe to optimize CTV_60Gy to CTV_50Gy in II_b region in patients with N₀‐N₁ NPC, and the exposure dose to normal tissues around the parotid gland and neck is significantly reduced. For small lymph nodes that do not meet the diagnostic criteria, it needs to be individualized in combination with multimodality imaging systems, such as PET‐CT and DWI.

Key words： Nasopharyngeal carcinoma Intensity‐modulated radiotherapy Clinical target volume Cervical lymph node Diffusion‐weighed imaging

收稿日期: 2021-09-01

基金资助:国家自然科学基金项目（81872192）; 江苏省卫健委重点项目（K2019028）; 江苏省科技厅社会发展重点项目（BE2019756）

通讯作者: 何侠,邮箱： hexiabm@163.com

引用本文:

黄文轩,宗丹,张彬等. 鼻咽癌N₀‐N₁期患者Ⅱb区临床靶区剂量优化策略及可行性分析[J]. 中华放射肿瘤学杂志, 2022, 31(9): 778-784.

Huang Wenxuan,Zong Dan,Zhang Bin et al. The strategy and feasibility of dose optimization in clinical target volume Ⅱb in patients with N₀‐N₁ nasopharyngeal carcinoma[J]. Chinese Journal of Radiation Oncology, 2022, 31(9): 778-784.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20210901-00336 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2022/V31/I9/778

[1] Ho FC, Tham IW, Earnest A, et al.Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta‐analysis of clinical evidence[J]. BMC Cancer, 2012, 12:98. DOI: 10.1186/1471‐2407‐12‐98.
[2] Wang X, Hu C, Ying H, et al. Patterns of lymph node metastasis from nasopharyngeal carcinoma based on the2013 updated consensus guidelines for neck node levels[J]. Radiother Oncol, 2015, 115(1):41‐45. DOI: 10.1016/j.radonc.2015.02.017.
[3] Tang L, Mao Y, Liu L, et al. The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging[J]. Cancer, 2009, 115(3):680‐688. DOI: 10.1002/cncr.24049.
[4] Lee N, Harris J, Garden AS, et al. Intensity‐modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial0225[J]. J Clin Oncol,2009, 27(22):3684‐3690. DOI: 10.1200/JCO.2008.19.9109.
[5] Lee NY, Zhang Q, Pfister DG, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG0615): a phase 2 multi‐institutional trial[J]. Lancet Oncol, 2012, 13(2):172‐180. DOI: 10.1016/S1470‐2045(11)70303‐5.
[6] Lee AW, Ng WT, Pan JJ, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiother Oncol, 2018, 126(1):25‐36. DOI: 10.1016/j.radonc.2017.10.032.
[7] 中国鼻咽癌临床分期工作委员会. 2010鼻咽癌调强放疗靶区及剂量设计指引专家共识[J].中华放射肿瘤学杂志, 2011, 20(4): 267‐269. DOI: 10.3760/cma.j.issn.1004‐4221.2011.04.001.
Chinese Nasopharyngeal Carcinoma Clinical Staging Committee.2010 expert consensus on target area and dose design guidelines for nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2011, 20(4): 267‐269. DOI: 10.3760/cma.j.issn.1004‐4221.2011.04.001.
[8] Cooper J, Fu K, Marks J, et al. Late effects of radiation therapy in the head and neck region[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1141‐1164. DOI: 10.1016/0360‐3016(94)00421‐g.
[9] van den Brekel MW, Stel HV, Castelijns JA, et al. Cervical lymph node metastasis: assessment of radiologic criteria[J]. Radiology, 1990, 177(2):379‐384. DOI: 10.1148/radiology.177.2.2217772.
[10] 黄素宁, 潘林江, 覃光灵, 等. N₀期鼻咽癌颈部可疑阳性淋巴结64Gy放疗疗效观察[J]. 肿瘤学杂志, 2013, 19(11): 868‐871. DOI: 10.11735/j.issn.1671‐170X.2013.11.B009.
Huang SN, Pan LJ, Qin GL, et al. The efficacy of cervical suspicious positive lymph nodes with 64 Gy radiotherapy in patients with nasopharyngeal cancer stage N₀[J]. J Chin Oncol, 2013,19(11): 868‐871. DOI: 10.11735/j.issn.1671‐170X.2013.11.B009.
[11] Peng G, Wang T, Yang KY, et al. A prospective, randomized study comparing outcomes and toxicities of intensity‐modulated radiotherapy vs. conventional two‐dimensional radiotherapy for the treatment of nasopharyngeal carcinoma[J]. Radiother Oncol, 2012, 104(3):286‐293. DOI: 10.1016/j.radonc.2012.08.013.
[12] Ng WT, Lee MC, Hung WM, et al. Clinical outcomes and patterns of failure after intensity‐modulated radiotherapy for nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2011, 79(2):420‐428. DOI: 10.1016/j.ijrobp.2009.11.024.
[13] Lee AW, Poon YF, Foo W, et al. Retrospective analysis of5037 patients with nasopharyngeal carcinoma treated during 1976‐1985: overall survival and patterns of failure[J]. Int J Radiat Oncol Biol Phys, 1992, 23(2):261‐270. DOI: 10.1016/0360‐3016(92)90740‐9.
[14] Lee A, Sham J, Poon Y, et al. Treatment of stage I nasopharyngeal carcinoma: analysis of the patterns of relapse and the results of withholding elective neck irradiation[J]. Int J Radiat Oncol Biol Phys, 1989, 17(6): 1183‐1190. DOI: 10.1016/0360‐3016(89)90524‐5.
[15] Wang L, Huang S, Zhang L, et al.Recommendation regarding the cranial upper border of level iib in delineating clinical target volumes (CTV) for nasopharyngeal carcinoma[J]. Radiat Oncol, 2020, 15(1):270. DOI: 10.1186/s13014‐020‐01720‐2.
[16] 徐文静, 陈震章, 王丽君, 等. 鼻咽癌调强放疗中上颈部CTV剂量优化对主要中线结构的保护[J]. 中华放射肿瘤学杂志, 2021, 30(5): 440‐445. DOI: 10.3760/cma.j.cn113030‐20201103‐00530.
Xu WJ, Chen ZZ, Wang LJ, et al. Effect of CTV dose optimization in upper and middle neck on protecting the main midline structures in intensity‐modulated radiotherapy for nasopharyngeal carcinoma[J].Chin J Radiat Oncol,2021,30(5):440‐445. DOI: 10.3760/cma.j.cn113030‐20201103‐00530.
[17] Rubira CM, Devides NJ, Ubeda LT, et al. Evaluation of some oral postradiotherapy sequelae in patients treated for head and neck tumors[J]. Braz Oral Res, 2007, 21(3):272‐277. DOI: 10.1590/s1806‐83242007000300014.
[18] Li Y, Taylor JM, Ten Haken RK, et al. The impact of dose on parotid salivary recovery in head and neck cancer patients treated with radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2007, 67(3):660‐669. DOI: 10.1016/j.ijrobp.2006.09.021.
[19] Eisbruch A, Kim HM, Terrell JE, et al. Xerostomia and its predictors following parotid‐sparing irradiation of head‐and‐neck cancer[J]. Int J Radiat Oncol Biol Phys, 2001, 50(3):695‐704. DOI: 10.1016/s0360‐3016(01)01512‐7.
[20] Eisbruch A, Ship JA, Dawson LA, et al. Salivary gland sparing and improved target irradiation by conformal and intensity modulated irradiation of head and neck cancer[J]. World J Surg, 2003, 27(7):832‐837. DOI: 10.1007/s00268‐003‐7105‐6.
[21] 王丽君,黄生富,蒋明华,等.鼻咽癌调强放疗临床靶区中Ⅱb区的优化对腮腺剂量的影响研究[J].肿瘤学杂志,2014, 20(10): 812‐818. DOI: 10.11735/j.issn.1671‐170X.2014.10.B007.
Wang LJ, Huang SF, Jiang MH, et al. The effect of optimizing clinical target volume in Ⅱb region on parotid gland dose in nasopharyngeal carcinoma treated with intensity modulated radiotherapy[J]. J Chin Oncol, 2014, 20(10): 812‐818. DOI: 10.11735/j.issn.1671‐170X.2014.10.B007.
[22] 王丽君,郭业松,张兰芳,等.鼻咽癌IMRT的CTV中Ⅱb区上界的探讨[J].中华放射肿瘤学杂志, 2016,(11): 1151‐1155. DOI: 10.3760/cma.j.issn.1004‐4221.2016.11.002.
Wang LJ, Guo YS, Zhang LF, et al. Upper bound of IIb region in clinical target volume for intensity‐modulated radiotherapy for nasopharyngeal carcinoma[J]. Chin J Radiat Oncol, 2016,(11): 1151‐1155. DOI: 10.3760/cma. j. issn. 1004‐4221.2016.11.002.
[23] Chen JZ, Le QT, Han F, et al. Results of a phase 2 study examining the effects of omitting elective neck irradiation to nodal levels IV and Vb in patients with N(0‐1) nasopharyngeal carcinoma[J]. Int J Radiat Oncol Biol Phys, 2013, 85(4):929‐934. DOI: 10.1016/j.ijrobp.2012.07.2356.
[24] 曾雷,陈春燕,孙学明,等.基于调强放疗N₀期鼻咽癌颈部预防照射的选择[J].中华放射肿瘤学杂志, 2013,(02): 133‐137. DOI: 10.3760/cma.j.issn.1004‐4221.2013.02.013.
Zeng L, Chen CY, Sun XM, et al. Volume of prophylactic irradiation to neck for stage N₀ nasopharyngeal carcinoma patients treated with intensity‐modulated radiotherapy[J]. Chin J Radiat Oncol, 2013,(02): 133‐137. DOI: 10.3760/cma.j.issn.1004‐4221.2013.02.013.
[25] Xiao F, Dou S, Li Y, et al. Omitting the lower neck and sparing the glottic larynx in node‐negative nasopharyngeal carcinoma was safe and feasible,improved patient‐reported voice outcomes[J]. Clin Transl Oncol, 2019, 21(6):781‐789. DOI: 10.1007/s12094‐018‐1988‐z.
[26] Sun Z, Wang J, Huang R, et al.Contralateral lower neck sparing radiotherapy in stage n1 nasopharyngeal carcinoma: long‐term survival outcomes and late toxicities[J]. Front Oncol, 2021, 11:628919. DOI: 10.3389/fonc.2021.628919.
[27] Vandecaveye V, De Keyzer F, Vander Poorten V, et al. Head and neck squamous cell carcinoma: value of diffusion‐weighted MR imaging for nodal staging[J]. Radiology, 2009, 251(1):134‐146. DOI: 10.1148/radiol.2511080128.
[28] Shen G, Xiao W, Han F, et al. Advantage of PET/CT in target delineation of mri‐negative cervical lymph nodes in intensity‐modulated radiation therapy planning for nasopharyngeal carcinoma[J]. J Cancer, 2017, 8(19):4117‐4123. DOI: 10.7150/jca.21582.